Amid ongoing angst over prescription drug prices, a new analysis found the median net price for 202 newly launched medicines, when adjusted for inflation and manufacturer discounts, rose by 35% to $257,000 last year, from $173,000 in 2022.
About one in four drugs launched in 2025 had an annual net price exceeding $500,000, while another 34% were priced between $200,000 and $500,000, according to the analysis by the Institute for Clinical and Economic Review, a nonprofit that assesses the value of medicines, and West Health, a nonprofit that advocates for lower health care costs.
Interestingly, the median list price for the drugs — also adjusted for inflation — rose 24% during that time, to $293,000. Normally, list prices are higher than net prices, since discounts are subtracted. The reasons for the divergence were not analyzed but indicate varying discounts for different types of drugs.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
Source: www.statnews.com
